InvestorsHub Logo
Followers 8
Posts 273
Boards Moderated 0
Alias Born 03/12/2007

Re: None

Friday, 07/17/2020 5:36:01 PM

Friday, July 17, 2020 5:36:01 PM

Post# of 233755
New article: Blocking inflammation on the way: Rationale for CXCR2 antagonists for the treatment of COVID-19

First clinical studies using the CCR5 antagonist ler- onlimab (NCT04343651, NCT04347239) and maraviroc (NCT04441385, NCT04435522), originally developed against HIV infection, for the treatment of COVID-19 are ongoing or planned to block the migration of inflamma- tory monocytes to the site of infection. Besides monocytes, several findings hint toward an active involvement of neutrophils in disease pathogenesis. Neutrophils are known to play an important role in the establishment of lung injury and ARDS

https://rupress.org/jem/article/217/9/e20201342/151957/Blocking-inflammation-on-the-way-Rationale-for
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CYDY News